1.	Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation Phase: Phase IV Type: Natural history/Epidemiology, Supportive care Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2007-005844-26, NCT00903188
2.	Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001JIL05, NCT01231659
3.	An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRAD001LDE36T, 2010-021370-11, NCT01266837
4.	Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001LDE43, 2011-003416-23, NCT01514448
5.	Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine Tumors Phase: Phase IV Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001K24133E1, NCT01595009
6.	Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001N2301, 2008-000498-40, NCT00790036
7.	CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial Phase: Phase III Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: 2007.489/32, NCT00799188
8.	Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001J2301, 2008-006556-21, NCT00876395
9.	Phase III Randomized Study of Everolimus Versus Placebo in Patients With Renal Cell Carcinoma Who Have Undergone Nephrectomy or Partial Nephrectomy Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S0931, S0931, NCT01120249
10.	Phase III Randomized Study of Everolimus With Versus Without Bevacizumab in Patients With Advanced Renal Cell Carcinoma That Progressed After First-Line Treatment With Tyrosine Kinase Inhibitors Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-90802, CALGB-90802, NCT01198158
11.	A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRAD001RDE35T, NCT01248403
12.	Caphosol in Oral Mucositis Due to Targeted Therapy Phase: Phase III Type: Supportive care Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: Esperanz-002, NCT01265810
13.	Everolimus Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (Gastro Intestinal or Lung Origin) Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001T2302, 2011-002887-26, NCT01524783
14.	4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Health services research, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001JDE49, NCT01626222
15.	Phase II Randomized Study of Adjuvant Endocrine Therapy With Versus Without Everolimus in Patients With High-Risk, Hormone Receptor-Positive, and HER2/neu-Negative Breast Cancer Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S1207, S1207, NCT01674140
16.	Study of BMS-936558 vs. Everolimus in Pre-Treated Advanced Or Metastatic Clear-cell RCC Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA209-025, 2011-005132-26, NCT01668784
17.	Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC) Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 20 to 75 Sponsor: Other Protocol IDs: CRAD001C2453, NCT00390195
18.	Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000544786, MAYO-LS0689, MAYO-07-000710, LS0689, NCT00474929
19.	RAD001 in Advanced Hepatocellular Carcinoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 06-352, NCT00516165
20.	Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 4P-09-4, AVF3955s, CRAD001CUS2468, NCT00574769
21.	Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MC0886, NCI-2009-00934, 08-004746, CLBH589BUS17T, NCT00918333
22.	Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 040803, P30CA072720, CDR0000648116, 0220090058, CRAD001C2448;, CINJ-040803, NOVARTIS-CINJ-040803, NCT00934895
23.	Everolimus (RAD001) and Carboplatin in Pretreated Metastatic Breast Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRAD001JDE15T, NCT00930475
24.	Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MC088C, NCI-2009-00935, 08-008775, NCT00935792
25.	RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2009-0100, NCT00968253